Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) Price Target at $7.43

Shares of Teladoc Health, Inc. (NYSE:TDOC) have been assigned an average recommendation of “Hold” from the seventeen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $7.6667.

TDOC has been the topic of a number of recent research reports. Citigroup raised their target price on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Tuesday, May 5th. Barclays cut their price target on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Bank of America lifted their price objective on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. cut their price objective on Teladoc Health from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, March 13th.

Teladoc Health Stock Performance

NYSE TDOC traded up $0.06 during trading hours on Monday, hitting $9.27. 2,279,446 shares of the company’s stock traded hands, compared to its average volume of 4,129,412. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.77. The firm has a market capitalization of $1.67 billion, a P/E ratio of -9.56 and a beta of 2.10. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75. The business’s fifty day moving average price is $7.53 and its two-hundred day moving average price is $6.37.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.01). Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The business had revenue of $613.85 million during the quarter, compared to the consensus estimate of $611.04 million. During the same quarter in the previous year, the business posted ($0.53) earnings per share. The firm’s revenue was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Equities research analysts predict that Teladoc Health will post -0.92 EPS for the current year.

Insider Activity

In other news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider directly owned 9,572 shares of the company’s stock, valued at $73,034.36. This represents a 37.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the sale, the chief executive officer owned 389,894 shares in the company, valued at $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,195 shares of company stock worth $299,058 in the last quarter. 0.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teladoc Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Teladoc Health by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after acquiring an additional 5,235 shares during the period. NewEdge Advisors LLC raised its stake in Teladoc Health by 1,278.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after purchasing an additional 10,485 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after purchasing an additional 24,124 shares in the last quarter. Acadian Asset Management LLC bought a new position in Teladoc Health in the 1st quarter worth approximately $615,000. Finally, Envestnet Asset Management Inc. bought a new position in Teladoc Health in the 2nd quarter worth approximately $89,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.